Inquiry
Accelerated & Innovative
Therapeutic Antibody Discovery
WIN Your Therapeutic Antibody Program at the Start Line
Mouse Monoclonal Antibody Development
In the 1970s, Cesar Milstein and George Kohler discovered the first mouse monoclonal antibody by hybridoma technology. Despite having a history of > 50 years, mouse monoclonal antibodies continue to be extensively used in research and therapeutic applications. In addition to traditional hybridoma technology, Yurogen Biosystems can use its own SMab™ platform in conjunction with BCR sequencing technology, to rapidly screen monoclonal antibodies from conventional mice to various types of human IgG transgenic mice.
Service Features
Unique DNA Immunization

Expertise in DNA immunization via gene gun or electroporation

High Positive Rate

Up to 10% antigen binding positive rate with electroporate cell fusion

Rapid Immunization Schedule

21 days rapid immunization schedule available.

One Stop Service

Offer various services including antibody isotype determination, hybridoma sequencing, recombinant antibody expression & antibody humanization etc.

Great Experience in mouse Hybridoma

Deliver more than 2,000 distinct mouse hybridoma cell lines

Expertise in Planning and Layout

Customizing immunization, screening, and sorting strategies for every project

Procedure
  • Phase I: Immunization
  • Phase II: Fusion & Screen
  • Phase III: Subclone
  • Phase IV: Production
Workflow
PhaseServiceDescriptionTimeline
Phase IImmunization

  • Standard Package: Immunize five mice for 6-9 weeks with 4 injections and 3 bleed collections
  • (Optional) Rapid Immunization: immunize five mice for 28 days with 2 times injection and 1 times’ bleed collection.
  • Bleed titer and blocking measured with ELISA
  • (Optional) Additional Assays: ELISA counter screen & FACS etc.
  • Client selects one (or more) mouse and isolate splenocytes for Electrofusion.
  • Phase I report

4-9 weeks
Phase IICell Fusion & 1st Round Screening

  • Electrofusion, and seed 10 (or more) 96-well-plates
  • Culture the fused cells with HAT selection.
  • High throughput ELISA screening for cultured supernatant.
  • Cherry pick the ELISA positive clones.
  • (Optional) Send the remaining supernatant to client, or do additional assays with blocking ELISA, FACS, WB or IHC etc.

2 weeks
Phase III Subclone & 2nd Round of Screening

  • Subclone the client selected fused clones: minimum 1 round of subclone for 10 96-well-plate;
  • High through ELISA for all subcloned cells.
  • Cherry pick ELISA positive clones & scale up culture
  • (Optional) Send the scale up supernatant to client, or do additional assays with blocking ELISA, FACS, WB or IHC etc.
  • Clients select up to five clones for final production & isotype determination.

2 weeks *
Phase IVAntibody Production

  • Antibody production using low serum hybridoma culture medium: ug to kg level capacity.
  • (optional) Hybridoma sequence and recombinant production of mouse mAbs.
  • Affinity purification of mouse mAbs, and QC with SDS-PAGE and/or Mass-spec, SEC-HPLC (optional)
  • Validation of purified mouse mAbs with ELISA, or (optional) blocking ELSA, FACS, WB & IHC etc.
  • Final project report.

3 weeks *
* Some hybridoma clones may need more than 2 rounds of subcloning and extra time.
** The timeline is based on no more than 5 hybridoma cells delivery.